Details of the Drug Combination

General Information of Drug Combination (ID: DCCWSTG)

Drug Combination Name

Topetecan Obatoclax

Indication

Disease Entry	Status	REF
Glioblastoma	Investigative	[1]

Component Drugs

Topetecan DMAE6LK

Obatoclax DMPF9ZM

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: JHH-136

Zero Interaction Potency (ZIP) Score: 41.719

Bliss Independence Score: 42.992

Loewe Additivity Score: 4.654

LHighest Single Agent (HSA) Score: 4.654

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Topetecan

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Approved	[2]

Topetecan Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

Indication(s) of Obatoclax

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]

Obatoclax Interacts with 3 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	TTL53M6	MCL1_HUMAN	Inhibitor	[3]
Apoptosis regulator Bcl-2 (BCL-2)	TTJGNVC	BCL2_HUMAN	Inhibitor	[3]
Apoptosis regulator Bcl-xL (BCL-xL)	TTU1E82	B2CL1_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
3	Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
4	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).